G. Giblin

Most-cited papers

1. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.

   J. Zakrzewska, J. Palmer, V. Morisset, G. Giblin +10 more

   2017Lancet Neurology165 citations Open access

   Semantic Scholar

   Save

2. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia

   J. Zakrzewska, J. Palmer, D. Ettlin, M. Obermann +4 more

   2013Trials50 citations Open access

   Semantic Scholar

   Save

3. Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia.

   D. Witty, Giuseppe S. Alvaro, D. Derjean, G. Giblin +10 more

   2020ACS Medicinal Chemistry Letters19 citations Open access

   Semantic Scholar

   Save

4. Evaluation of the Pharmacokinetic Interaction Between the Voltage‐ and Use‐Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers

   J. Dunbar, M. Versavel, Yuan Zhao, S. Tate +5 more

   2019Clinical pharmacology in drug development13 citations

   Semantic Scholar

   Save

5. Sodium Channel Blockers for the Treatment of Pain

   D. Witty, D. Macpherson, G. Giblin

   20174 citations

   Semantic Scholar

   Save

6. (386) A novel proof of concept, placebo controlled, randomised withdrawal study, demonstrating the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia

   S. Tate, J. Palmer, V. Morisset, G. Giblin +4 more

   20151 citations Open access

   Semantic Scholar

   Save

7. (387) A novel proof of concept, randomized, double blind, cross-over study demonstrating the safety and efficacy of CNV1014802 in subjects with neuropathic pain from lumbosacral radiculopathy

   S. Tate, J. Palmer, V. Morisset, G. Giblin +2 more

   20151 citations Open access

   Semantic Scholar

   Save